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Abstract: More appropriate and measured use of antibiotics may be achieved using point-of-care 
(POC) C-reactive protein (CRP) testing, but there is limited evidence of cost-effectiveness in routine 
practice. A decision analytic model was developed to estimate the cost-effectiveness of testing, 
compared with standard care, in adults presenting in primary care with symptoms of acute 
respiratory tract infection (ARTI). Analyses considered (1) pragmatic use of testing, reflective of 
routine clinical practice, and (2) testing according to clinical guidelines. Threshold and scenario 
analysis were performed to identify cost-effective scenarios. In patients with symptoms of ARTI and 
based on routine practice, the incremental cost-effectiveness ratios of CRP testing were £19,705 per 
quality-adjusted-life-year (QALY) gained and £16.07 per antibiotic prescription avoided. Following 
clinical guideline, CRP testing in patients with lower respiratory tract infections (LRTIs) cost £4,390 
per QALY gained and £9.31 per antibiotic prescription avoided. At a threshold of £20,000 per QALY, 
the probabilities of POC CRP testing being cost-effective were 0.49 (ARTI) and 0.84 (LRTI). POC 
CRP testing as implemented in routine practice is appreciably less cost-effective than when adhering 
to clinical guidelines. The implications for antibiotic resistance and Clostridium difficile infection 
warrant further investigation. 
Keywords: economic evaluation; cost–utility analysis; cost-effectiveness analysis; antibiotics; 
primary care; respiratory tract infection; point-of-care testing; C-reactive protein; antimicrobial 
resistance; Clostridium difficile 
 
1. Introduction 
Respiratory tract infections (RTI) are the most common presenting complaint in primary care 
and the most common reason for antibiotic prescribing in Europe [1]. Whilst antibiotics will benefit 
lower respiratory tract infections (LRTI) of bacterial origin, they are often prescribed inappropriately, 
such as for viral upper RTI, putting patients at risk of adverse effects with limited or no therapeutic 
benefit [2]. Identifying patients presenting with bacterial LRTI that require an antibiotic represents a 
challenge to healthcare professionals. Unnecessary antibiotic prescribing also increases the risk of 
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development of antimicrobial resistance [2–5] and Clostridium difficile infection [6]. The vital 
importance of addressing antimicrobial resistance at a local, national and international level is widely 
recognized [7]. O’Neill’s report for the United Kingdom (U.K.) government [8], the National Institute 
of Health and Care Excellence (NICE) guidelines on antimicrobial stewardship [9], and the Welsh 
Government delivery plan for Wales “Tackling antimicrobial resistance and improving antibiotic 
prescribing” [10], all highlight the urgency of the task.  
To avoid unnecessary use of antibiotics, the NICE advises considering point-of care (POC) C-
reactive protein (CRP) testing in primary care in patients presenting with symptoms of LRTI, when 
clinical assessment is not conclusive and it is not clear whether antibiotics should be prescribed [11]. 
The clinical guideline recommends that antibiotic therapy should not be routinely offered if the CRP 
is <20 mg/L; a delayed antibiotic prescription should be considered if the CRP is 20–100 mg/L; and 
antibiotic therapy should be offered if the CRP is >100 mg/L [11].  
In Wales, the national policy is for wider use of POC CRP testing as a prognostic tool in primary 
care to aid clinical decisions about the appropriateness of antibiotic prescribing [12]. Implementation 
of POC CRP testing across Wales requires a clear understanding of the potential costs and benefits 
associated with its use. A meta-analysis including 10,005 patients showed that CRP testing was 
associated with a significant reduction in antibiotic prescribing at index consultation but not at 28-
day follow-up, and did not impact on patient satisfaction [13]. A more recent review [14] suggested 
that reductions in antibiotic prescribing attributable to POC CRP testing range from 23% to 36% [15–
19]. Economic evaluations of POC CRP testing in managing RTIs suggest potential cost savings [20–
23]; however, these are of variable quality and based on key assumptions concerning the effectiveness 
of implementation of POC CRP testing, laboratory support costs, and connectivity to wider 
healthcare systems [24]. A formal analysis of the cost effectiveness of CRP testing in patients 
presenting with acute respiratory tract infection (ARTI) in the context of routine National Health 
Service (NHS) primary care service delivery, which considers the full costs of implementation, is 
therefore required. Given the objective of POC CRP testing is to reduce unnecessary antibiotic 
prescribing in order to conserve the effectiveness of current antimicrobials, economic evaluations of 
POC CRP testing have the added challenge of how best to capture the cost of antimicrobial resistance 
[25].  
The aim of the economic evaluation was to estimate the cost-effectiveness of POC CRP testing 
of adult patients presenting with symptoms of ARTI in routine use, acknowledging widespread non-
compliance with clinical guidelines, and to compare this with the cost-effectiveness of testing 
according to clinical protocol. The study design is an economic model based on empirical data from 
a published study [26]. This is the first study, to our knowledge, to consider the influence on the cost-
effectiveness of POC CRP testing of deviations from clinical guidelines—such as prescribing 
antibiotics regardless of test result—that are common occurrences in routine practice. Evidence 
generated by this evaluation suggests pragmatic use of POC CRP testing is considerably less cost-
effective than when adhering to clinical guidelines, and that including the cost of antimicrobial 
resistance in the model improves the cost-effectiveness of POC CRP testing. 
2. Results 
2.1. Base Case Analysis 
The study population had a median age of 48.5 years, and 69% were female (one participant out 
of 71 was lost to follow-up and was excluded from the analysis) [26]. The mean number of CRP tests 
received over 28 days was 1.03 per patient, at a cost of £9.85 (95% CI 9.63 to 10.42). With POC CRP 
testing 18/70 patients received antibiotics (Table 1). At least 10 of these prescriptions would be 
considered unnecessary according to CRP testing guidelines (143/1000 prescriptions). Compared 
with standard care, the modelled incremental cost of the POC CRP strategy in the ARTI population, 
compared to standard care, was £11.92 (95% CI 9.35 to 15.39); the main cost drivers were the costs of 
the test and re-consultation. Modelled differences in quality-adjusted-life-years (QALYs) between 
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standard care and POC CRP were 0.0006 (95% CI −0.0006 to 0.0019), which is equivalent to 
approximately five additional hours of perfect health over 28 days. The base-case incremental cost-
effectiveness ratio (ICER) is therefore £19,705 per QALY gained. The cost-effectiveness of POC CRP 
testing for ARTI is estimated to be £16.07 per antibiotic prescription avoided (£11.25 per 1% reduction 
in antibiotic prescribing).  
Table 1. Cost effectiveness of point-of-care (POC) C-reactive protein (CRP) testing for adults with 
symptoms of acute respiratory tract infection (ARTI) for >12 h where the antibiotic decision is unclear 
versus immediate antibiotic prescription. QALY: quality-adjusted-life-year. 
Results for 28 days and 1 patient Intervention Control Increment Ratio 
Pragmatic use of testing, reflective of 
practice 
Mean 95% CI 95% CI Mean 95% CI 95% CI Mean 95% CI 95% CI  
Costs (£) 
Consultation cost 41.75 39.36 44.71 37.46 37.39 37.54 4.28 1.91 7.26  
CRP testing 9.85 9.63 10.42 0.00 0.00 0.00 9.85 9.63 10.42  
Antibiotic prescription 0.74 0.47 1.04 2.89 2.85 2.89 −2.15 −2.41 −1.84  
ADR to antibiotic prescription 0.02 0.01 0.02 0.06 0.05 0.07 −0.04 −0.06 −0.03  
Total cost 52.35 49.76 55.79 40.41 40.32 40.48 11.94 9.35 15.39  
Effectiveness 
Antibiotic prescription avoided 0.74 0.64 0.84 0.00 0.00 0.01 0.74 0.64 0.84  
Cost-effectiveness           
£/prescription avoided (over 28 days)          16.07 
Utility           
QALY (for 28 days) 0.0615 0.0512 0.0706 0.0609 0.0507 0.0700 0.0006 −0.0006 0.0019  
Cost–utility 
£/QALY          19,705 
Probabilistic result %          
Probability cost-effective at £20,000 49.06          
Probability cost-effective at £30,000 62.82          
Results for 28 days and 1 patient Intervention Control Increment Ratio 
Adhering to guidelines Mean 95% CI 95% CI Mean 95% CI 95% CI Mean 95% CI 95% CI  
Costs (£) 
Consultation cost 38.73 36.90 42.76 36.89 36.70 37.06 1.84 0.05 5.85  
CRP testing 10.05 9.58 10.68 0.00 0.00 0.00 10.05 9.58 10.68  
Antibiotic prescription 0.00 0.00 0.00 2.53 2.42 2.53 −2.53 −2.47 −1.86  
ADR to antibiotic prescription 0.00 0.00 0.00 0.06 0.05 0.07 −0.06 −0.07 −0.04  
Total cost 48.79 46.66 53.53 39.48 39.25 39.62 9.31 7.24 14.11  
Effectiveness 
Antibiotic prescription avoided (N) 1.00 0.75 0.98 0.00 0.00 0.04 1.00 0.73 0.98  
Cost-effectiveness           
£/prescription avoided (over 28 days)          £9.31 
Utility           
QALY (for 28 days) 0.0577 0.0536 0.0612 0.0556 0.0509 0.0594 0.0021 −0.0011 0.0058  
Cost–utility 
£/QALY          £4,390 
Probabilistic result %          
Probability cost-effective at £20,000 84.10          
Probability cost-effective at £30,000 86.33          
2.2. Sensitivity and Scenario Analyes 
2.2.1. One-Way Sensitivity and Threshold Analyses 
The threshold analysis revealed that if each POC CRP test were 18 pence more expensive, the 
ICER would exceed £20,000 per QALY gained (Table 2). If CRP test usage were to fall by 5% (from 37 
to 35 tests/1000 patient-years) the ICER for ARTI will exceed £20,000 per QALY. Adjusting the 
proportion of patients seen by a general practitioner (GP) or independent nurse prescriber (INP) 
consultation varied the ICER from £16,288 to £19,749 per QALY.  
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Table 2. Results of scenario and sensitivity analyses. GP: general practitioner; INP: independent 
nurse prescriber; LRTI: lower respiratory tract infection; ICER: incremental cost-effectiveness ratio. 
No. Scenario 
ARTI Pragmatic 





  ICER ICER 
 Base case £19,705 £4390 
 Threshold analysis   
 Cost of test   
 Cost of test = £0 £3449 DOMINANT 
 Cost of test = +£0.18 (£9.76) ~2% increase £20,010 n/a 
 Cost of test = +£31.60 (£41.18) (4-fold increase) n/a £20,036 
 Scale of testing: number of tests per year (base case = 376)   
 ARTI only (n = 280 test per practice per annum) £21,834 n/a 
 LRTI only (n = 80 test per practice per annum) n/a £11,094 
 5% decrease (358 tests per practice per year) £20,017 n/a 
 90% decrease (39 tests per practice per year) n/a £20,046 
 One-way sensitivity analysis   
 Healthcare professional at index and re-consultation   
 GP: INP 50:50 £18,081 £4193 
 GP £19,749 £4410 
 Nurse £16,288 £3976 
 Scenario analyses   
i Re-consultation rate   
 Equal in each arm i.e. standard care = CRP pilot study £12,638 £3520 
ii Cost of antimicrobial resistance per prescription over 28 days   
a European £19,525 £4321 
a U.S. £13,854 £2140 
b Global Dominant Dominant 
iii Dispensing item fee at local dispensing doctor rate £1.90 £19,361 £4258 
iv Hospital admission £26,927 £ 6454 
v Antibiotic prescribing in standard care 53% £20,277 £4533 
vi Amoxicillin prescription   
 500 mg capsules three times daily for 5 days £20,146 n/a 
 500 mg capsules three times daily for 7 days n/a £4220 
vii CRP analyser machine life 10-years £19,183 £4238 
2.2.2. Probabilistic Sensitivity Analysis 
The cost-effectiveness plane for the ARTI base case analysis is illustrated in Figure 1. The 
distribution of the simulations indicates that POC CRP testing results in higher utility (health gain) 
but at higher cost in 75% of simulations. The corresponding cost-effectiveness acceptability curve 
(CEAC) indicates the probabilities of POC CRP testing for ARTI being cost-effective were 0.49 and 
0.63 at the £20,000 and £30,000 per QALY thresholds, respectively (Figure 2).  












Point estimate £20,000/QALY Threshold




Figure 2. Cost effectiveness acceptability curve (CEAC) for pragmatic use of POC CRP testing. 
2.2.3. Scenario Analyses 
The scenario of restricting CRP testing to patients with symptoms of LRTI for >12 hours; is 
represented by a sub-group of 20 patients with a median age 48.5 years, 55% female. Based on the 
observed CRP test results for the study population (no CRP >100 mg/L [26], the model predicts a 
100% reduction in antibiotic prescribing at an incremental cost of £9.31 per patient (95% CI 7.24 to 
14.11) (Table 1). The increase in total cost is attributable to the cost of POC CRP testing (£10.05 per 
patient), which is not outweighed by the savings in antibiotic prescribing costs (−£2.53 per patient). 
The cost–utility analysis indicates that POC CRP testing for LRTI, according to protocol, is associated 
with a 0.0021 QALY gain (95% CI −0.0011 to 0.0058), equivalent to about 19 quality-adjusted hours, 
with a resulting ICER of £4390 per QALY gained. There is capacity for test prices to increase 4-fold 
before the ICER reaches the £20,000 per QALY threshold. Probabilistic sensitivity analysis for this 
scenario indicates that POC CRP testing is associated with increased QALYs and higher cost in 88% 
of simulations and a probability of being cost-effective at a threshold of £20,000 per QALY threshold, 
of 0.84.  
Additional scenarios indicate that the ICER decreases (i) under the assumption of equal re-
consultation rates for both standard care and CRP testing, regardless of antibiotic prescribing; (ii,a) 
when accounting for antimicrobial resistance; (iii) when a 7-day course of amoxicillin is dispensed by 
a doctor; and (vii) if the machine-life is extended to 10-years. POC CRP testing is dominant when 
(ii,b) the cost of each antibiotic prescription includes the global cost of treating antimicrobial 
resistance [27]. POC CRP testing is less cost-effective (higher ICER) when the model includes (iv) 
hospitalizations related to ARTI; or (v) a lower rate of antibiotic prescribing in standard care (53%) 
reduces the cost-effectiveness (increases the ICER). Testing is no longer cost-effective if (vi) 
prescribing guidelines are adhered to (5-day instead of 7-day course of amoxicillin).  
3. Discussion 
3.1. Key Findings  
The model suggests that as implemented in routine primary care (for all adults with symptoms 
of ARTI for >12 hours where the antibiotic decision unclear) POC CRP testing is borderline cost-
effective [28]. There are a number plausible scenarios where testing outside the recommendations of 
the NICE clinical guideline exceeds the cost-effectiveness threshold. Closer adherence to the NICE 
CRP recommendation, however, by restricting testing to adults with symptoms of LRTI, and 
prescribing appropriate courses of antibiotics, results in a more favourable ICER. The main cost 
driver is the cost of a CRP test which, for ARTI must be below £9.76 per test to be considered cost-
effective. This represents a small increase (+£0.18) from the current estimate, that may easily be caused 
by changes in unit costs or throughput (such as a 5% increase in agent costs, £6/month increase in 
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Including the cost of antimicrobial resistance in the model improves the cost-effectiveness of POC 
CRP testing, but there are uncertainties associated with specifying this cost, and resistance would 
also affect the efficacy of the antibiotic, which was not explicitly considered in this analysis. This 
evaluation did, however, identify a 74% absolute reduction in antibiotic prescribing (from 70 to 18 
prescriptions) and an 89% reduction in unnecessary prescribing for adults with ARTI. It is plausible 
that reductions in unnecessary prescribing could conserve the effectiveness of current antimicrobials.  
3.2. Comparisons to Other Studies 
We are aware of four published economic evaluations of POC CRP testing for RTI. Cals et al. 
(2011) conducted a cost-effectiveness analysis of POC CRP testing by GP versus standard care based 
on data from a cluster randomised factorial clinical trial of 431 patients with LRTIs recruited in 40 GP 
practices [20]. They reported an ICER of €5.79 per 1% reduction in antibiotic prescribing 
(corresponding to £4.02). Oppong et al., (2013) conducted an economic evaluation based on an 
observational study of the presentation, management, and outcomes of patients with acute cough 
and LRTI in primary care settings in Norway and Sweden, and reported an ICER of €9,391 per QALY 
gained [23]. NICE based their analysis on the incremental QALY (0.0012) reported by Oppong et al. 
(2013) [23] to estimate an ICER of £15,763 per QALY gained [11]. This included the cost of 
hospitalization, as evaluated in our scenario analysis. More recently, Hunter (2015) conducted an 
analysis which included both hospitalizations and the costs of complications of antibiotic prescribing, 
and reported CRP testing dominates current practice [22]. Studies of POC CRP testing are 
characterized by uncertainty that may be attributable to valuation of the test, heterogeneity in study 
population, and the subjectivity of the indication. Regents were 75% of costs in the analysis by Cals 
et al. (2011) [20], but accounted for only 37% the current analysis; whilst the proportion of cost 
attributable to reagent was similar in the analysis by Hunter (2015) [22], costs were limited to reagent, 
depreciation and staff time. Other studies provide no details of what was included in the valuation 
[11,23]. Defining the eligible patient population requires a subjective judgement, i.e. “where the 
antibiotic decision is unclear”, and this represents a challenge for economic modelling. By 
considering the use of testing as routinely implemented in practice, our analysis reflects the 
judgements of GPs.  
3.3. Strengths 
To our knowledge, this is the first study in the UK to model the cost-effectiveness of POC CRP 
testing using data from actual usage of testing, and to include support costs for the management of 
POC testing in primary care. The probabilities in the model were based on individual patient-level 
data, undertaken over 3 months, in a GP surgery that had a high rate of antibiotic prescribing. The 
analysis, therefore, reflected the real world situation of protocol deviations and provides an estimate 
of the cost-effectiveness (as opposed to the cost-efficacy) of testing. Unlike previous studies, our 
analyses also attempted to incorporate the long-term cost implications of antimicrobial resistance. 
3.4. Limitations 
The time horizon of the model is unable to assess the longer-term effects of unnecessary 
antibiotic prescribing, such as the increased antibiotic resistance and increased risk of Clostridium 
difficile infection [5,29]. The scenario analysis of antibiotic resistance is limited to a projected cost and 
is not reflective of patients’ health-related quality of life. The utilities associated with RTI are baseline 
estimates and the model assumes this is constant for the duration of the illness; due to a lack of 
disaggregated longitudinal data. The disutility of common adverse events, such as diarrhoea, are 
assumed to be captured by time to full recovery, which may underestimate resource use and 
overestimate utility associated with antibiotic prescribing. Finally, this model is representative of 
outlying practice. The estimate of 100% prescribing of antibiotics in standard care, and non-
compliance to POC CRP guidelines, is less likely in other places.  




This analysis highlights the reduction in cost-effectiveness attributable to protocol deviation, as 
is expected in a routine clinical setting. The cost-effectiveness of the POC CRP testing strategy is 
highly sensitive to the cost of the test, therefore when interpreting the result in other settings; 
consideration should be given to test cost drivers, such as machine throughput. Economies of scale 
are likely to be limited by the size of the practice population and uptake of the test by healthcare 
professionals.  
3.6. Future Research Directions 
Further research is required to capture the effects of antimicrobial resistance and increased risk 
of Clostridium difficile infection, both of which are associated with increased NHS costs [27,29], 
morbidity and mortality; and has long term impacts on health-related quality of life and society 
[29,25]. The appropriateness of QALYs for use in evaluation of acute conditions, such as respiratory 
tract infections, warrants further exploration; alternative methods such as willingness to pay have 
been suggested [30]. Beyond the testing strategy, research is also required on behavioural aspects, 
such as protocol adherence by healthcare professionals and the influence on the test on medication 
adherence by the patients. 
How best to assess the value of any intervention to reduce antimicrobial resistance is a 
methodological challenge, which requires adequate measurement of the expected rate of growth of 
antimicrobial resistance and associated outcomes over time [31]. Rothery and colleagues [31] recently 
outlined a framework for value assessment of new antimicrobials that involves modelling to estimate 
the infection transmission dynamics, associated resistance, and economic outcomes, for alternative 
treatment strategies. The report outlines several implications for health technology assessment [31]. 
Modelling the infection transmission dynamics and resistance outcomes over time is complex and 
relies on the multidisciplinary teams (mathematical modelers, epidemiologist, data experts, clinical 
experts, and health economists). There is greater reliance on observational data and dynamic 
transition modelling rather than cohort statistic modelling. This is associated with more extensive 
and systematic use of expert elicitation methods and model calibration for interring values for 
unobservable parameters and limited efficacy data. Furthermore, there are difficulties in measuring 
and valuing health—with limited data on utility values, difficulty measuring health related quality 
of life in short severe infections, and difficulty measuring the costs of onward transmission of 
infections to the wider population. Typical health technology appraisal, such as that conducted by 
NICE, is based on the “average” patient receiving a treatment for a specified indication. When 
considering the consequences of antibiotic prescribing benefits and costs extend to a wider 
population, within which diversity in settings (e.g., community care, intensive care) will influence 
the spread of infections in the population. Given this population level, Rothery and colleagues, also 
highlight the issue of an indefinite time horizon [31]. Future research therefore needs to address the 
challenge of how to formally characterize the value of interventions with the potential to reduce 
antimicrobial resistance and to measure the opportunity cost used to guide this longer term and more 
global decision. Rothery and colleagues suggest the following uncertainties need to be considered: 
prevalence of infections, resistance patterns over time, stock of future antibiotics, lag periods before 
resistance, irreversible impacts. Future research also needs to consider a broader perspective to 
explore issues such as the insurance value of avoiding major health consequences if antimicrobial 
resistance becomes substantially worse [25], and antibiotic use in farming with associated events, for 
example, standards relating to the import of diary and meat into the United Kingdom and associated 
trade deals on departure from the European Union [32].  
4. Materials and Methods  
We conducted a cost-effectiveness analysis of antibiotic prescribing conditional on POC CRP 
testing for adults presenting in primary care (GP practice) with symptoms of ARTI for >12 hours 
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versus immediate antibiotic prescription (current standard of care). The analysis had a 28-day time 
horizon, conducted from the perspective of the NHS in the United Kingdom. 
4.1. Economic Model 
A decision analytic model was developed with a time horizon of 28 days from the index 
consultation (Figure 3). The model was structured to represent the following care pathways [11]: (1) 
standard care, in which patients receive no test (as per current practice) and instead receive an 
antibiotic prescription for immediate use, and (2) a strategy of testing for CRP, where patients are 
prescribed an antibiotic for immediate or (3) delayed use [33]. Patients who are offered a delayed 
prescription are offered a prescription for use at a later date if symptoms worsen. The model accounts 
for whether or not a delayed prescription, issued at the index consultation (based on CRP 20–100 
mg/L), is dispensed. 
The model also takes account of re-consultations occurring within 28 days where patients on the 
CRP testing pathway receive no antibiotic prescriptions (CRP <20 mg/L). At re-consultation, the 
model considers whether or not patients receive a repeat CRP test and thereafter, whether antibiotics 
are prescribed or not. Patients who were not going to receive an antibiotic prescription irrespective 
of testing did not enter the model. 
 
Figure 3. Decision tree for pragmatic use of POC CRP testing, reflective of practice *Amoxicillin 500 
mg tds x7. 
4.1.1. Clinical Parameters  
The model was parameterized using data from purposive reviews of the literature, in line with 
standard methodology for populating economic models [34]. These supplemented data from a 
published study [26] undertaken in a general practice surgery that serves 10,200 patients in Anglesey, 
North Wales, UK. The practice was in the top one percentile in England and Wales for antibiotic 
prescribing [35]. A POC CRP analyser was introduced in November 2015 and used for 3 months, 
based on the NICE clinical guideline for pneumonia [11]. POC testing was supported by a laboratory 
POCT team as specified by national policy [12]. Within the study [26], data were collected on POC 
CRP test results, antibiotic decision, re-consultation within 28 days for the same complaint, and, the 
outcome of any decision to prescribe antibiotics at any re-consultation. Dispensing of delayed 
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prescriptions within 28 days of the index consultation was determined by retrospective review of the 
online NHS Wales Shared Services “primary care prescribing catalogue” [36]. Patients who were lost 
to follow-up were excluded from the analysis. Clinical parameter estimates (probabilities) are listed 
in Table 3.  
The standard care arm of the economic model is based on routine clinical practice at the same 
location. We assumed that 100% of patients (adults with symptoms of ARTI for 12 or more hours 
where the antibiotic decision is unclear) in the standard care arm of the model received an immediate 
prescription. Re-consultation rates in the standard care arm were modelled on the rate of re-
consultation in the CRP pilot study for patients who received antibiotics at index consultation (0% at 
28 days; [26].  
All patients in the model had a risk of hypersensitivity reaction to antibiotic therapy that is 
independent of CRP testing strategy or re-consultation rates. As there were no recorded cases of 
adverse drug reactions in the pilot study, the probability of anaphylaxis was taken as that for 
amoxicillin, and assumed to be 1 in 10,000 people [37].  
4.1.2. Resource Use and Costs 
Resource use included GP or INP index and re-consultation, CRP testing, antibiotic prescription 
and treatment of adverse drug reactions. The rate of index consultation and subsequent consultations, 
and the proportion of patients who consulted with a GP or INP, face-to-face or by telephone, was 
taken from Hughes et al., (2016) [26] and assumed to be the same for CRP testing as for standard care. 
Re-consultation with the same complaint occurred in 7/50 cases with URTI and 1/20 cases with LRTI. 
The cost of a consultation was based on a mean duration of 9.22 minutes with a GP [38] and assumed 
to be 15 minutes with an INP (Table 3). Costs of GP and nurse-led telephone triage were based on 
national figures [39].  
Antibiotic prescriptions were assumed to be amoxicillin 500-mg capsules three times daily for 7-
days, informed by retrospective review of prescribing at the GP practice involved in the study, where 
there were no records of a 5-day course being prescribed (as recommended). Local prescribing data 
showed that in this primary care cluster, 22% of amoxicillin prescriptions (all indications) were 
prescribed for 5 days. Prescription costs were taken from the British National Formulary at the Drug 
Tariff price [40]. An additional dispensing fee was included for every dispensed prescription, based 
on the mean dispensing rate per item for community pharmacists at the location [41].  
The cost of a managing an anaphylaxis reaction consisted of ambulance treatment and transport, 
followed by emergency medicine investigation and treatment [41,42]. The model assumed all patients 
who experience a hypersensitivity reaction survive and are prescribed clarithromycin as an 
alternative antibiotic.  
The cost of CRP testing included the cost of performing a test using the Alere Afinion AS100 
analyser (Alere; MA, United States) (Table 4). This included the fixed cost of purchasing the analyser 
and variable costs of its use in clinical practice. Variable costs included consumables, internal quality 
control (IQC), external quality assurance (EQA), maintenance costs, connectivity, and hospital-based 
laboratory POC testing team assistance. Extra equipment was required to connect the analyser into 
the All Wales Laboratory Information System (LIMS), with the added cost of a company to connect 
the analyser so that results can be viewed in the patient record. The cost per test was calculated 
assuming a machine life of 5 years, based on the manufactures estimate, and the projected annual 
number of tests based on the number of test performed in 3 months [26]. In the base-case analysis, 
the test was assumed to be performed by a health care assistant (HCA), in addition to the standard 
consultation with GP/INP.  
  
Antibiotics 2018, 7, x 10 of 19 
 
 




Distribution 1 References 
Probabilities 
Antibiotics at index | CRP > 100 mg/L 1.00 Fixed [11] 
Antibiotics at index consultation | no CRP 1.00 Fixed Assumption 2 
Anaphylactic reaction to antibiotic prescription 0.0001 Beta (1, 10, 000) [37] 
ARTI Observed Data 
CRP < 20 mg/L 0.77 Dirichlet (54, 16, 0) [26] 
CRP 20–100 mg/L 0.23 Dirichlet (16, 54, 0) [26] 
No antibiotics at index consultation | CRP < 20 mg/L 0.93 Dirichlet (50, 2, 2) [26] 
Delayed prescription at index consultation | CRP < 20 mg/L 0.04 Dirichlet (2, 50, 2) [26] 
Delayed prescription at index consultation not dispensed | CRP < 20 
mg/L 
1.00 Beta (1, 0) [26] 
Antibiotics at index consultation | CRP < 20 mg/L 0.04 Dirichlet (2, 50, 2) [26] 
No antibiotics at index consultation | CRP 20–100 mg/L 0.38 Dirichlet (6, 10, 0) [26] 
Antibiotics at index consultation | CRP 20–100 mg/L 0.63 Dirichlet (10, 6, 0) [26] 
No re-consultation within 28 days | CRP < 20 mg/L 0.86 Beta (43, 7) [26] 
No re-consultation within 28 days | CRP 20–100 mg/L 0.83 Beta (5, 1) [26] 
No repeat CRP at re-consultation| CRP < 20 mg/L 0.71 Beta (5, 2) [26] 
No repeat CRP at re-consultation| CRP 20–100 mg/L 1.00 Beta (1, 0) [26] 
CRP guided no antibiotic decision at re-consultation | CRP <20 mg/L 1.00 Beta (2, 0) [26] 
Antibiotics at re-consultation | CRP < 20 mg/L at index, CRP not 
repeated at re-consultation 
1.00 Beta (5, 0) [26] 
Antibiotics at re-consultation | CRP 20–100 mg/L at index, no 
delayed prescription, CRP not repeated at re-consultation 
1.00 Beta (1, 0) [26] 
Resource Use Proportions 
GP face-to-face consultation for LRTI 0.95 Beta (20, 1) Raw data [26] 
GP face-to-face consultation for ARTI 0.99 Beta (77, 1) Raw data [26] 
INP face-to-face consultations for LRTI 0.05 Beta (1, 20) Raw data [26] 
GP face-to-face consultation for ARTI 0.01 Beta (1, 77) Raw data [26] 
Telephone triage 5 0.01 Beta (1, 77) Raw data [26] 
Costs (per unit)    
GP consultation (9.22 minutes) £38.00 Fixed [39] 
INP consultation (band 7 @ 15 minute consultation) £13.25 Fixed [39] 
Telephone triage GP led (per telephone call) £14.60 Fixed [39] 
Telephone triage nurse led (per telephone call) £6.10 Fixed [39] 
POC CRP testing (per test) £9.58 Fixed Table 4 
Amoxicillin capsules (500 mg tds 5 days) £0.91 Fixed [40] 
Amoxicillin capsules (500 mg tds 7 days) £1.27 Fixed [40] 
Clarithromycin tablets (500 mg bd 14 tablets) £2.23 Fixed [40] 
Dispensing rate for community pharmacists (per item) £1.62 Fixed [41] 
Emergency ambulance 3 (per ADR) £236.00 Fixed [43] 
Emergency medicine 4 (per ADR) £362.00 Fixed [43] 
Utilities 
Utility (EQ-5d-3L scores) 6    












Anaphylaxis weight 0.5 Fixed [45] 
Symptom Duration (days) Median   
Patient reported time to full recovery_LRTI_CRP 15.5 Beta (2.8, 5.5) [48] 
Patient reported time to full recovery _LRTI_Standard care 20 Beta (4.4, 4.5) [48] 
Patient reported time to full recovery _URTI_CRP 14 Beta (2.3, 6.2) [48] 
Patient reported time to full recovery _URTI_Standard care 14 Beta (2.0, 7.0) [48] 
1 Distribution used in probabilistic sensitivity analysis 2 Standard care for symptoms of ARTI for >12 h where the 
antibiotic decision is unclear. 3 National average unit cost for Ambulance ASS02 See and treat and convey. 4 
National average unit cost for VB01Z Emergency Medicine, Any Investigation with Category 5 Treatment. 5 
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Telephone triage lead ratio assumed to be equal to face-to-face ratio in the LRTI according to protocol model. 6 
Utilities for 365 days have been adjusted in the 28-day model. 
Table 4. Cost of POC CRP testing according to the CRP POCT Guidelines for Wales 
Heading Cost (£) n £ Per Test References / Assumptions 
Resource Use 
Number of tests per GP practice - 376 - 
Projected from Hughes (2016) 
[26] assuming constant rate of 
uptake 
Estimated life of the CRP Analyser (years) - 5 - Manufacturer quote (Alere) 
Fixed Costs 
Afinion CRP analyser 1500.00 - - 
Alere Afinion AS100 analyser 
(Alere; MA, United States) 
Connectivity 120.00 - - BCUHB estimate 
Printer 250.00 - - Equal life to analyser 
Scanner 125.00 - - Equal life to analyser 
Total analyser set-up cost 1995.00 - 1.06 
Calculated using machine life 
and number of tests per year 
Annual Costs 
Associated connectivity cost 20.00 - 0.05 BCUHB estimate 
IQC 136.00 - 0.36 Guidelines for Wales [51] 
EQA (WEQAS) 240.00 - 0.64 Guidelines for Wales [51] 
Laboratory support 
(including travel, training, competency, 
clinical interpretation, quality, and 
troubleshooting support) 
468.92 - 1.25 
BCUHB estimate based on mid-
point of AFC scale 2017 at each 
band and 28.1% on costs 
Maintenance cost (annual after 3-years) 280 - 0.30 3-year warrantee 
Total annual support costs £976.92 - 2.60  
Variable costs 
Cartridge/reagent (per test) - - 3.50  
Health care assistant (HCA) time - - 2.42 Band 4 for 5 minutes [39] 
Total variable costs - - £5.92  
Total cost per test - - £9.58  
1 Price year 2016–2017. 
4.1.3. Health State Utilities 
Health state utilities were estimated for presenting complaint (Table 3). The utility associated 
with LRTI was the mean EQ-5D-3L value at baseline for patients in Wales (n = 181) participating in 
an observational study of the management of patients with acute cough and LRTI in primary care 
[1,47]. For URTI, the decrement used in the NICE Clinical Guideline on antibiotic prescribing for 
respiratory tract infections [44,45], was applied to the U.K. age-specific population norm [46]. The 
utility of each RTI was assumed constant for the duration of symptoms [48], after which patients 
returned to the UK age-specific population norm [46]. Duration of symptoms associated with LRTI 
and URTI was the length of time from index consultation to patient-reported full recovery, from a 
study of patients with LRTI and rhinosinusitis [48]. Quality-adjusted life-years (QALYs) were then 
calculated for the 28-day time horizon of the model.  
The model used price year 2016–2017 for all costs. Discounting was not required due to short 
time horizon of the model.  
4.2. Analysis 
4.2.1. Cost Per QALY 
The primary analysis for POC CRP testing for adults with symptoms of ARTI for >12 hours, 
versus, immediate antibiotic prescription, resulted in the calculation of the incremental cost-
effectiveness ratio (ICER), as follows: 




𝐶𝑂𝑆𝑇𝑤𝑖𝑡ℎ 𝑡𝑒𝑠𝑡 − 𝐶𝑂𝑆𝑇𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑐𝑎𝑟𝑒:𝑛𝑜 𝑡𝑒𝑠𝑡
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4.2.2. Cost-Effectiveness Analysis  
A secondary, cost-effectiveness of POC CRP testing considered the cost per antibiotic 
prescription avoided. The ICER was calculated as the incremental cost divided by the total number 
of prescriptions avoided (N Prescriptions with test, N Prescriptions standard care with no test). 
4.2.3. Base-Case Analysis 
The care pathways in the base-case analysis allowed for deviation from the NICE guideline [11] 
by including all adult patients (including upper RTI) and reflecting the real world use of CRP testing. 
This used observational data to reflect actual clinical practice [26] which exhibits variable compliance 
with clinical and prescribing guidelines.  
4.2.4. Sensitivity Analyses 
A threshold analysis was conducted to establish the cost and throughput of testing at which the 
ICER met the NICE cost-effectiveness threshold of £20,000 per QALY [28]. A one-way sensitivity 
analysis was conducted on the probability that patients are seen by GP or INP at index and re-
consultation. Probabilistic sensitivity analysis was also performed, using Monte Carlo simulation 
with 10,000 replications sampled from the distributions presented in Table 3. A CEAC was 
constructed to illustrate the probability of testing being cost-effective at given thresholds of cost-
effectiveness [49]. 
4.2.5. Scenario Analyses  
The NICE guidance advises that POC CRP testing should only be used for patients presenting 
with symptoms of LTRI for >12 hours, where the antibiotic decision is unclear. A scenario analysis 
was therefore conducted, assuming that all patients are treated according to the NICE (2014) 
guideline [11], and that if antibiotics were required, they were prescribed amoxicillin 500 mg three 
times daily for 5 days (BCUHB Adult Antimicrobial Guide). The model structure is displayed in 
Figure 4. 
Alternative modelled scenarios considered: (1) the possibility that patients would re-consult in 
standard care at the same rate as following POC CPR testing, irrespective of antibiotic outcome; (2) 
the impact of inappropriate prescribing on antibiotic resistance, based on costs extracted from 
Oppong et al., (2016) [27]; (3) antibiotics being dispensed by doctors rather than by community 
pharmacists, as might happen in more rural settings, and using local rates (personal communication; 
(4) the impact of hospitalizations related to ARTI on the cost-effectiveness of testing, based on 
published probabilities for CRP (0.009) and standard care (0.003) [11]; (5) the probability of reduced 
antibiotic prescribing in standard care (to 53%) [11]; and (6) the prescribing of 5 days’ supply of 
amoxicillin for ARTI (as per guideline); and (7) machine-life extended to 10-years. All parameter 
values used in the scenario analyses are detailed in table 5. The three estimates for the cost of 
antibiotic resistance were based on the annual cost of resistance in the United States (U.S.) ($55 billion) 
[50], the cost of multidrug resistance in the European Union (EU) (1.5 billion euro) [51], and the cost 
of global resistance over a 35-year period ($2.8 trillion annually) [8]. Oppong and colleagues [27] 
estimated the cost per prescription in each scenario by calculating the cost of annual cost of resistance, 
divided by the annual number of prescriptions in each region—assuming antibiotic prescribing is the 
main cause of resistance. In the current analysis, estimates were converted into pounds sterling and 
then inflated to price year 2016–2017.  




Figure 4. Decision tree for POC CRP testing adhering to guidelines, LRTI only. * Amoxicillin 500 mg 
tds x5. 




Distribution 1 Assumptions / References 
 
LRTI per protocol 
Probabilities 
   
 CRP < 20 mg/L 0.70 Dirichlet (14, 6, 0) Raw data [26] 
 CRP 20–100 mg/L 0.30 Dirichlet (6, 14, 0) Raw data [26] 
 
No antibiotics at index consultation 
| CRP < 20 mg/L 
1.00 Dirichlet (14, 0, 0) [11], Raw data [26] 
 
Delayed prescription at index 
consultation | CRP 20–100 mg/L 
1.00 Dirichlet (6, 0, 0) [11], Raw data [26] 
 
Delayed prescription not dispensed| 
CRP 20–100 mg/L 
1.00 Beta (1, 0) [26] 
 
No re-consultation within 28 days | 
CRP < 20 mg/L 
0.93 Beta (13, 1) 
Raw data [26] LRTI re-consultation 
with CRP < 20 mg/L 
 
Re-consultation within 28 days | 
CRP 20–100 mg/L 
0.00 Beta (0, 1) 
Raw data [26] LRTI re-consultation 
with CRP 20–100 mg/L 
 
Repeat CRP at re-consultation| CRP 
< 20 mg/L 
1.00 Beta (1, 0) 
Assumption: CRP repeated at re-
consultation if used at index 
consultation. 
 
No antibiotics at re-consultation | 
CRP < 20 mg/L 
1.00 Beta (0, 1) 
Assumption: antibiotics only 
indicated at CRP > 100 mg/L; 
Hughes et al. (2016) [26] reports no 
evidence of CRP > 100 mg/L 
i 
Probability ARTI re-consultation 
standard care = CRP study data 
0.1143  [26] 
 
LRTI re-consultation 
standard care = CRP pilot study 
0.0500  Raw data [26] 
ii 
Cost of antimicrobial resistance per 
prescription over 28 days2 
   
a European £0.15  [27] 
a U.S. £4.77  [27] 
b Global £17.83  [27] 
iii 
Cost of dispensing 
Item dispensing fee for dispensing 
doctor 
£1.90  [41] 




Cost and probability of hospital 
admission 
Cost of hospital admission for 
presenting complaint3 
£826.69  [43] 
 
Probability of hospital admission: 
POC CRP test 
0.0088  [11] 
 
Probability of hospital admission: 
standard care 
0.0035  [11] 
v 
Probability of antibiotic use in 
standard care 
   
 Antibiotic prescribing: standard care 0.53  [11] 
vi Cost of amoxicillin prescription    
 
Amoxicillin capsules: 500 mg tds 5 
days 
£0.91  [40] 
 
Amoxicillin capsules: 500 mg tds 7 
days 
£1.27  [40] 
vii CRP analyser machine life 10-years 10-years  Assumption 
1 Distribution used in probabilistic sensitivity analysis 2 Currency conversion and inflation calculations applied. 3 
Unit cost for on total HRG activity (excluding excess bed days) DZ22Q Unspecified Acute Lower Respiratory 
Infection, without Interventions, with CC Score 0-4. 
All analyses were performed in Microsoft Excel 2010 (Microsoft Corp., Redmond, WA, USA) 
and the study is reported according to the Consolidated Health Economic Evaluation Reporting 
Standards [52] [Appendix A]. 
5. Conclusions 
POC CRP testing for adults where the antibiotic decision is unclear, is borderline cost-effective, 
however the results are favourable when restricted to patients with LRTI symptoms only adhering 
to protocol. Modelling pragmatic use of testing, reflective of practice, using observed data that 
deviated from protocols for both CRP-guided prescribing, and the length of prescription thereafter; 
illustrated the potential for variation in cost-effectiveness in clinical practice. POC testing for patients 
with upper respiratory tract infection is less likely to be cost-effective and comes with a higher 
opportunity cost for alternative use of NHS resources. The results of this economic evaluation are 
subject to considerable uncertainty, and therefore further empirical research is necessary.  
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Appendix A 
CHEERS checklist—Items to include when reporting economic evaluations of health interventions. 







Reported on page No/ 
line No 
Title and abstract 
Title 1 
Identify the study as an economic evaluation or use 
more specific terms such as “cost-effectiveness 
analysis”, and describe the interventions compared. 
Lines 2-4 
Abstract 2 
Provide a structured summary of objectives, 
perspective, setting, methods (including study design 
and inputs), results (including base case and 
uncertainty analyses), and conclusions. 
Lines 18-32 
Introduction 
Background and objectives 3 
Provide an explicit statement of the broader context for 
the study. 
Lines 38-56 
Present the study question and its relevance for health 
policy or practice decisions. 
Lines 74-83 
Methods 
Target population and 
subgroups 
4 
Describe characteristics of the base case population and 
subgroups analysed, including why they were chosen. 
Lines 273-276 
Lines 315-320 
Setting and location 5 
State relevant aspects of the system(s) in which the 




Study perspective 6 
Describe the perspective of the study and relate this to 
the costs being evaluated. 
Line 275 
Comparators 7 
Describe the interventions or strategies being compared 
and state why they were chosen. 
Lines 282-287 
Time horizon 8 
State the time horizon(s) over which costs and 
consequences are being evaluated and say why 
appropriate. 
Line 280 
Discount rate 9 
Report the choice of discount rate(s) used for costs and 
outcomes and say why appropriate. 
Line 384 
Choice of health outcomes 10 
Describe what outcomes were used as the measure(s) of 
benefit in the evaluation and their relevance for the 





Single study-based estimates: Describe fully the design 
features of the single effectiveness study and why the 







Synthesis-based estimates: Describe fully the methods 
used for identification of included studies and 
synthesis of clinical effectiveness data. 
Measurement and valuation 
of preference based 
outcomes 
12 
If applicable, describe the population and methods 
used to elicit preferences for outcomes. Lines 373-382 
Estimating resources and 
costs 
13a 
Single study-based economic evaluation: Describe 
approaches used to estimate resource use associated 
with the alternative interventions. Describe primary or 
secondary research methods for valuing each resource 
item in terms of its unit cost. Describe any adjustments 
made to approximate to opportunity costs. 
 
13b 
Model-based economic evaluation: Describe 
approaches and data sources used to estimate resource 
use associated with model health states. Describe 
primary or secondary research methods for valuing 
each resource item in terms of its unit cost. Describe 




Currency, price date, and 
conversion 
14 
Report the dates of the estimated resource quantities 
and unit costs. Describe methods for adjusting 
estimated unit costs to the year of reported costs if 
necessary. Describe methods for converting costs into a 
common currency base and the exchange rate. 
Lines 328-385 
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For consistency, the CHEERS statement checklist format is based on the format of the CONSORT statement 
checklist. 
References 
1. Butler, C.C.; Hood, K.; Verheij, T.; Little, P.; Melbye, H.; Nuttall, J.; Kelly, M.J.; Mölstad, S.; Godycki-Cwirko, 
M.; Almirall, J.; et al. Variation in antibiotic prescribing and its impact on recovery in patients with acute 
cough in primary care: Prospective study in 13 countries. BMJ 2009, 338, b2242. 
Choice of model 15 
Describe and give reasons for the specific type of 
decision-analytical model used. Providing a figure to 




Describe all structural or other assumptions 
underpinning the decision-analytical model. 
Lines 280-385 
Analytical methods 17 
Describe all analytical methods supporting the 
evaluation. This could include methods for dealing 
with skewed, missing, or censored data; extrapolation 
methods; methods for pooling data; approaches to 
validate or make adjustments (such as half cycle 
corrections) to a model; and methods for handling 
population heterogeneity and uncertainty. 
Lines 413--445 
Results 
Study parameters 18 
Report the values, ranges, references, and, if used, 
probability distributions for all parameters. Report 
reasons or sources for distributions used to represent 
uncertainty where appropriate. Providing a table to 
show the input values is strongly recommended. 
Table 3 
Incremental costs and 
outcomes 
19 
For each intervention, report mean values for the main 
categories of estimated costs and outcomes of interest, 
as well as mean differences between the comparator 





Single study-based economic evaluation:Describe the 
effects of sampling uncertainty for the estimated 
incremental cost and incremental effectiveness 
parameters, together with the impact of methodological 
assumptions (such as discount rate, study perspective). 
 
20b 
Model-based economic evaluation: Describe the effects 
on the results of uncertainty for all input parameters, 







If applicable, report differences in costs, outcomes, or 
cost-effectiveness that can be explained by variations 
between subgroups of patients with different baseline 
characteristics or other observed variability in effects 





Study findings, limitations, 
generalisability, and current 
knowledge 
22 
Summarise key study findings and describe how they 
support the conclusions reached. Discuss limitations 
and the generalisability of the findings and how the 
findings fit with current knowledge. 
Lines 154-169 
Other 
Source of funding 23 
Describe how the study was funded and the role of the 
funder in the identification, design, conduct, and 
reporting of the analysis. Describe other non-monetary 
sources of support. 
Line 461 
Conflicts of interest 24 
Describe any potential for conflict of interest of study 
contributors in accordance with journal policy. In the 
absence of a journal policy, we recommend authors 
comply with International Committee of Medical 
Journal Editors recommendations. 
Line 467 
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